TTPH - Tetraphase Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue9,6665,14511,686
Cost of Revenue---
Gross Profit9,6665,14511,686
Operating Expenses
Research Development101,70663,76473,768
Selling General and Administrative23,67519,21120,916
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-115,715-77,830-82,998
Income from Continuing Operations
Total Other Income/Expenses Net963350-191
Earnings Before Interest and Taxes-114,752-77,480-83,189
Interest Expense---
Income Before Tax-114,752-77,480-83,189
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-114,752-77,480-83,189
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-114,752-77,480-83,189
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-114,752-77,480-83,189